Zymeworks (ZYME) Reiterated at Market Outperform by Citizens After Q1 Results

May 11, 2026 4:19 AM

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $32.00 price target on Zymeworks (NASDAQ: ZYME).The analyst commented, "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found